U.S. markets close in 5 hours 5 minutes

Emmaus Life Sciences, Inc. (EMMA)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.6200-0.0900 (-5.26%)
As of 10:38AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.7100
Bid0.0000 x 1800
Ask0.0000 x 1300
Day's Range1.6200 - 1.6400
52 Week Range0.7000 - 1.8900
Avg. Volume7,312
Market Cap79.885M
Beta (5Y Monthly)1.34
PE Ratio (TTM)N/A
EPS (TTM)-0.0130
Earnings DateSep 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Daily – Vickers Top Insider Picks for 09/22/2021The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    8 hours agoArgus Research
View more
  • PR Newswire

    OTC Markets Group Welcomes Emmaus Life Sciences, Inc. to OTCQX

    OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company, has qualified to trade on the OTCQX® Best Market. Emmaus Life Sciences, Inc. upgraded to OTCQX from the Pink® market.

  • Benzinga

    3 Penny Stocks Insiders Are Buying

    When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Emmaus Life Sciences The Trade: Emmaus Life Sciences, Inc. (OTC: EMMA) Chairman and CEO Yutaka Niihara acquired a total of

  • PR Newswire

    Emmaus Life Sciences Reports Financial Results for the Six Months Ended June 30, 2021

    Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced financial results for the six months ended June 30, 2021. As a result, the company is now current in its Securities and Exchange Commission (SEC) reporting obligations.